Pacer Advisors Inc. Sells 823,914 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Pacer Advisors Inc. cut its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 39.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,246,520 shares of the company’s stock after selling 823,914 shares during the quarter. Pacer Advisors Inc. owned approximately 2.71% of Omnicell worth $54,348,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. raised its position in Omnicell by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock valued at $165,200,000 after purchasing an additional 80,312 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Omnicell by 0.3% in the second quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company’s stock worth $31,955,000 after acquiring an additional 3,570 shares during the period. Victory Capital Management Inc. grew its holdings in Omnicell by 11,982.3% during the 3rd quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock worth $50,071,000 after acquiring an additional 1,138,921 shares in the last quarter. Federated Hermes Inc. increased its position in Omnicell by 1,113.6% during the 2nd quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock valued at $26,830,000 after purchasing an additional 909,480 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. bought a new stake in shares of Omnicell in the 3rd quarter valued at about $32,721,000. Institutional investors own 97.70% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on OMCL shares. Craig Hallum lifted their price objective on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Benchmark reiterated a “buy” rating and issued a $48.00 price target on shares of Omnicell in a report on Wednesday, October 9th. Wells Fargo & Company upped their price objective on Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research note on Monday, October 14th. JPMorgan Chase & Co. lifted their target price on Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research note on Thursday. Finally, StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, Omnicell currently has an average rating of “Hold” and an average target price of $52.00.

Omnicell Stock Up 5.5 %

NASDAQ:OMCL opened at $44.11 on Friday. The stock has a market capitalization of $2.04 billion, a PE ratio of -113.10, a price-to-earnings-growth ratio of 35.67 and a beta of 0.81. Omnicell, Inc. has a 52 week low of $25.12 and a 52 week high of $55.74. The stock’s 50-day moving average price is $44.19 and its 200-day moving average price is $37.20.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.